| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9018e575c930fa852fd6d8cdfee3d41a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f71d4dc5ed0705923000f69ed0da2925
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3dd543259881a2803432b8fa3f6c1161
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_272ea18b3dd4d594d378c254e901a449 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 |
| filingDate |
2004-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03e32a827fd73ecb57f0db296a39b6a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a07dbbcaf71011d9d2ab9783d63842a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4f01ac53b65b639c969d55a6cb5019c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ef69232c55f7d46b68d618ea603bf70 |
| publicationDate |
2005-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2546622-A1 |
| titleOfInvention |
Use of isogenic drug-resistant cell lines to determine the sequence of chemotherapeutic drug treatment |
| abstract |
The present invention provides isogenic cell lines and uses said isogenic cell lines in a method for determining a sequence to administer multiple types of chemotherapeutic drugs for killing cancerous cells to reduce the induction of drug cross-resistance in a patient. The methods also involves screening drug candidates to select a lead anticancer drug from amongst a plurality of candidate drugs, the lead having a reduced capacity to induce cross resistance in a patient against one or more known anticancer drugs, and all of the drugs having the ability to kill cancerous cells of the same selected tumour type. Moreover, the methods involve determining a sequence to administer multiple types of cytotoxic drugs for killing undesired cells to reduce the indication of drug cross-~resistance in the cells. |
| priorityDate |
2003-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |